<DOC>
	<DOCNO>NCT02789332</DOCNO>
	<brief_summary>This multicenter , prospective , randomize , open-label phase II study evaluate efficacy safety PO→EC neoadjuvant treatment operable locally advanced breast cancer patient HR deficiency . Patients randomize receive - paclitaxel 80 mg/m² iv weekly combination olaparib tablet 100 mg ( 4X25mg ) twice daily 12 week ( 65 patient ) - paclitaxel 80 mg/m² iv weekly combination carboplatin AUC 2 iv weekly 12 week ( 37 patient ) follow 4 cycle epirubicin 90 mg/m² cyclophosphamide 600 mg/m² ( EC ) either every 3 every 2 week follow surgery . The control arm choose allow direct comparison one currently consider standard care regimen .</brief_summary>
	<brief_title>Assessing Efficacy Paclitaxel Olaparib Comparison Paclitaxel / Carboplatin Followed Epirubicin/Cyclophosphamide Neoadjuvant Chemotherapy Patients With HER2-negative Early Breast Cancer Homologous Recombination Deficiency</brief_title>
	<detailed_description>The efficacy olaparib germline HRD score high without BRCA 1/2 mutation carrier breast cancer well describe - The efficacy safety olaparib include standard care regimen like paclitaxel weekly follow epirubicin cyclophosphamide ( Pw -- &gt; EC ) unknown - Carboplatin increase pCR rate patient triple-negative breast cancer ( TNBC ) two randomized phase II neoadjuvant study add anthracycline , cyclophosphamide paclitaxel ( GeparSixto , CALBG 40603 ) . pCR rate even high patient germline BRCA 1 2 mutation ( ypT0/is ypN0 65 % ) HRD score high ( ypT0/is ypN0 63 % ) . - The TNT study show double response rate patient receive carboplatin v docetaxel patient germline BRCA 1 2 mutation . - There high correlation tumor germline BRCA 1/2 mutation . - Data Geparsixto study show triple negative breast patient HR deficiency 70 % ( 67 % high HRD 30 % tBRCA mutation ) - About 5 % tBRCA patient low HRD score - gBRCA2 patient older diagnose likely HRpos tumor . - The GeparOLA study aim support decision phase III study explore addition olaparib Pw -- &gt; EC schedule provide estimate pCR rate target population also provide estimate comparison paclitaxel carboplatin follow epirubicin cyclophosphamide ( PCb -- &gt; EC ) carboplatin consider standard option care HR deficient patient ( tBRCA 1/2 mutation and/or HRD score high ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Written inform consent study specific procedure accord local regulatory requirement prior begin specific protocol procedure . 2 . Complete baseline documentation must send GBG Forschungs GmbH . 3 . Unilateral bilateral primary carcinoma breast , confirm histologically core biopsy . Fineneedle aspiration alone sufficient . Incisional biopsy allow . In case bilateral cancer , investigator decide prospectively side evaluated primary endpoint . 4 . Centrally confirm negative HER2status . Centrally confirm estrogen progesterone receptor , Ki67 status detect core biopsy . ER/PR positive define ≥1 % stain cell HER2positive define IHC 3+ insitu hybridisation ( ISH ) ratio ≥2.0 . Formalinfixed , paraffinembedded ( FFPE ) breast tissue core biopsy therefore send Dept . Pathology Charité , Berlin prior randomization . 5 . Centrally confirm tumor Homologous Recombinant Deficiency score ( tBRCA positive/mutated and/or HRD high ) . Patients know gBRCA and/or tBRCA status enrol prior central test result available . 6 . Tumor lesion breast palpable size &gt; 2 cm sonographical size &gt; 1 cm maximum diameter . If tumor detectable sonography mammography assessment consider . The lesion measurable two dimension , preferably sonography . In case inflammatory disease , extent inflammation use measurable lesion . 7 . Patients must follow stage disease : cT2 cT4ad cT1c cN+ cT1c pNSLN+ cT1c ERneg PRneg cT1c Ki67 &gt; 20 % In patient multifocal multicentric breast cancer , large lesion measure least one lesion meet criterion 8 . Age &gt; 18 year . 9 . Karnofsky Performance status index ≥ 80 % . 10 . Normal cardiac function must confirm ECG cardiac ultrasound ( LVEF shorten fraction ) within 3 month prior randomization . Results must normal limit institution . 11 . Laboratory requirement : Hematology Absolute neutrophil count ( ANC ) ≥2.0 x 109 / L Platelets ≥100 x 109 / L Hemoglobin ≥10 g/dL ( ≥ 6.2 mmol/L ) Hepatic function Total bilirubin ≥1.5x UNL ASAT ( SGOT ) ALAT ( SGPT ) ≥1.5x UNL Alkaline phosphatase ≥2.5x UNL . 12 . Negative pregnancy test ( urine serum ) within 14 day prior randomization woman childbearing potential . 13 . Complete stag workup within 3 month prior randomization . All patient must bilateral mammography , breast ultrasound ( ≥21 day , case exceed 6 week prior randomization ) ( Note MRI/ CT scan may use alternative imaging technique ) . In case high risk accord guideline : chest Xray ( PA lateral ) alternative breast MRI/CT , abdominal ultrasound CT scan MRI , bone scan case high risk primary metastasis accord guideline . In case positive bone scan , bone Xray CT scan mandatory . Other test may perform clinically indicate . 14 . Male female patient 15 . Patients must available compliant central diagnostics , treatment followup . 1 . Prior chemotherapy malignancy within 5 year . 2 . Prior radiation therapy breast cancer within 5 year . 3 . Pregnant lactating patient . Patients childbearing potential must implement adequate nonhormonal contraceptive measure ( barrier method , intrauterine contraceptive device , sterilization ) study treatment . 4 . Inadequate general condition ( fit anthracyclinetaxanetargeted agentsbased chemotherapy ) . 5 . Previous malignant disease without diseasefree less 5 year ( except CIS cervix nonmelanomatous skin cancer ) . 6 . Known suspected congestive heart failure ( &gt; NYHA I ) / coronary heart disease , angina pectoris require antianginal medication , previous history myocardial infarction , evidence transmural infarction ECG , uncontrolled poorly control arterial hypertension ( i.e . BP &gt; 140 / 90 mm Hg treatment two antihypertensive drug ) , rhythm abnormality require permanent treatment , clinically significant valvular heart disease . 7 . History significant neurological psychiatric disorder include psychotic disorder , dementia seizure would prohibit understanding give informed consent . 8 . Patients currently institution order jurisdictional governmental ground . 9 . Currently active infection . 10 . Definite contraindication use corticosteroid . 11 . Known hypersensitivity reaction one compound incorporated substance use protocol . 12 . Concurrent treatment : chronic corticosteroid unless initiate &gt; 6 month prior study entry low dose ( 10 mg less methylprednisolone equivalent ) . sex hormone . Prior treatment must stop study entry . experimental drug anticancer therapy . 13 . Participation another clinical trial investigational , market drug within 30 day prior study entry . 14 . Prior use PARPInhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>carboplatin</keyword>
	<keyword>olaparib</keyword>
	<keyword>pCR</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>triple-negative</keyword>
	<keyword>hormonreceptor-positive</keyword>
	<keyword>BRCA1/2</keyword>
	<keyword>HRD , homologous recominant deficient</keyword>
	<keyword>breast cancer</keyword>
	<keyword>genetic testing ( somatic germline mutation )</keyword>
</DOC>